Retrospective Study
Copyright ©The Author(s) 2018.
World J Gastroenterol. Nov 21, 2018; 24(43): 4928-4938
Published online Nov 21, 2018. doi: 10.3748/wjg.v24.i43.4928
Table 1 Clinicopathological data of patients with gastric cancer and their relation with the presence or absence of Helicobacter pylori, Helicobacter pylori-cagA, Epstein-Barr virus and human papil-lomavirus

HP-
HP+

CagA-
CagA+

EBV-
EBV+

HPV-
HPV+

n (%)38 (13)264 (87)P (95%CI)98 (23)204 (77)P (95%CI)240 (80)62 (20)P (95%CI)294 (97)8 (3)P (95%CI)
Gender
Male195 (65)25 (66)170 (64)0.866 (0.46-1.92)60 (61)135 (66)0.400 (0.75-2.04)152 (63)43 (69)0.377 (0.72-2.39)192 (65)3 (37)0.105 (0.75-1.36)
Fem107 (35)13 (34)94 (36)38 (39)69 (34)88 (37)19 (31)102 (35)5 (63)
Age
≥ 55201 (67)24 (63)177 (67)0.635 (0.58-2.41)65 (66)136 (67)0.953 (0.61-1.69)157 (65)44 (71)0.409 (0.70-2.38)201 (68)0 (0)0.000 (1.03-1.15)
< 55101 (33)14 (37)87 (33)33 (34)68 (33)83 (35)18 (29)93 (32)8 (100)
Localization
Proximal104 (34)14 (36)90 (34)0.837 (0.46-1.87)37(38)67 (33)0.400 (0.49-1.33)81 (34)23 (37)0.621 (0.65-2.07)100 (34)4 (50)0.348 (0.47-7.92)
Distal198 (66)25 (64)173 (66)61 (62)137 (67)159 (66)39 (63)194 (66)4 (50)
Subtype
Intestinal166 (55)14 (37)152 (58)0.016 (1.15-4.70)48 (49)118 (58)0.147 (0.88-2.32)127 (53)39 (63)0.159 (0.85-2.70)164 (56)2 (25)0.084 (0.05-1.33)
Diffuse136 (45)24 (63)112 (42)50 (51)86 (42)113 (47)23 (37)130 (44)6 (75)
TNM
T
T1-T270 (23)10 (27)60 (23)0.624 (0.38-1.79)27 (28)43 (21)0.212 (0.40-1.22)56 (23)14 (23)0.900 (0.49-1.87)65 (22)5 (62)0.008 (1.37-25.22)
T3-T4232 (77)28 (73)204 (77)71 (72)161 (79)184 (77)48 (77)229 (78)3 (38)
N
N016 (5)2 (5)14 (5)0.992 (0.22-4.55)5 (5)11 (5)0.916 (0.32-2.79)13 (5)3 (5)0.856 (0.31-4.08)16 (5)0 (0)0.498 (0.92-0.97)
N1-N3286 (95)36 (95)250 (95)93 (95)193 (95)227 (95)59 (95)278 (95)8 (100)
M
M0141 (47)18 (47)123 (47)0.928 (0.52-2.04)48 (49)93 (46)0.580 (0.71-1.86)121 (50)20 (32)0.011 (1.18-3.85)137 (47)4 (50)0.849 (0.21-3.55)
M1161 (53)20 (53)141 (53)50 (51)111 (54)119 (50)42 (68)157 (53)4 (50)
EBV
EBV+62 (20)7 (18)55 (21)0.731 (0.49-2.79)9 (9)53 (26)0.001 (1.63-7.37)
EBV-240 (80)31 (82)209 (79)89 (91)151 (74)
HPV
HPV+8 (3)0 (0)8 (3)0.277 (1.01-1.05)1 (1)7 (3)0.222 (0.42-28.41)6 (2)2 (3)0.751 (0.26-6.60)
HPV-294 (97)38 (100)256 (97)97 (99)197 (97)234 (98)60 (97)
Table 2 Ratio, in absolute value and percentage, between pathogen (Helicobacter pylori, Epstein-Barr virus, and human papillomavirus), strain (HPcagA) and tumor location
InfectionCardia (104)P (OR, 95%CI)Fundus (57)P (OR, 95%CI)Body (45)P (OR, 95%CI)Antrum (95)P (OR, 95%CI)
HP+ (263)91 (34.6%)0.975 (OR = 1.012, 95%CI: 0.494-2.071)44 (16.7%)0.012 (OR = 0.395, 95%CI: 0.188-0.831)40 (15.2%)0.704 (OR = 1.213, 95%CI: 0.447-3.291)88 (33.5%)0.064 (OR = 2.214, 95%CI: 0.938-5.228)
H. pylori-cagA+ (203)67 (33%)0.400 (OR = 0.806, 95%CI: 0.488-1.332)27 (13.3%)0.000 (OR = 0.361, 95%CI: 0.201-0.648)35 (17.2%)0.092 (OR = 1.886, 95%CI: 0.894-3.978)74 (36.5%)0.009 (OR = 2.087, 95%CI: 1.191-3.656)
EBV+ (62)23 (37.1%)0.621 (OR = 1.158, 95%CI: 0.648-2.069)1 (1.6%)0.000 (OR = 0.053, 95%CI: 0.007-0.388)16 (25.8%)0.009 (OR = 2.435, 95%CI: 1.227-4.833)22 (35.5%)0.444 (OR = 1.258, 95%CI: 0.699-2.266)
HPV+ (8)4 (50%)0.348 (OR = 1.940, 95%CI: 0.475-7.920)0 (0%)0.162 (OR = 0.803, 95%CI: 0.758-0.850)2 (25%)0.436 (OR = 1.894, 95%CI: 0.370-9.686)2 (25%)0.690 (OR = 0.720, 95%CI: 0.143-3.637)